Reimbursement and value assessment frameworks: ensuring patients’ access to asthma medicines in Ukraine
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2017, Vol 1, Issue 1
Abstract
Background. Health technology assessment (HTA) introduction and implementation for development of the National List of Essential Medicines (NLEM) took place in Ukraine in 2016 in the context of National Drug Policy until 2025. The study aimed to outline the reimbursement of medicines for asthma treatment, market access for innovative medicines, main steps of HTA development in the decision making process in Ukraine in line with the international requirements and future directions. Methods. Literature review was conducted examining legislation database and scientific publications on the study issues in Ukraine: epidemiology of asthma, reimbursement programs, HTA development, affordability of innovative medicines for asthma treatment, market analysis. The study was performed to investigate the practices, processes and policies of value assessment and their impact in Ukraine. Results. In 2016 a legal framework was developed for the elaboration of NLEM and procedures for reference pricing and reimbursement programs. HTA is used for the inclusion medicines on the list based on the applied evidence of quality, efficacy, effectiveness, safety and economic evaluations adhering to the Order of Ministry of Health (MoH). HTA implementation in 2016 consisted of legislation, HTA training for experts of Expert committee of MoH and development of NLEM. Reimbursement programs for cardiovascular diseases, type 2 diabetes (T2D), asthma have started in April 2017 due to the adopted regulations. Conclusions. HTA use in the decision-making in Ukraine will provide an access to innovative medicines for patients and transparent, consistent decision making process in assessing the health technologies for inclusion on regulatory lists and reimbursement programs.
Authors and Affiliations
Olha Zaliska, Oresta Pinyazhko, Roman Ilyk, Hryhoriy Irynchyn
Keywords
Related Articles
- EP ID EP326179
- DOI 10.7365/JHPOR.2017.1.5
- Views 60
- Downloads 0
Idiopathic Pulmonary Fibrosis as a Challenge for the Polish Healthcare System
Idiopathic pulmonary fibrosis (IPF) is a rare disease characterised by age-dependent incidence, unclear aetiology and progressive course. Given the complexity of the diagnostic pathway and limited therapeutic options, an...
Cost-effectiveness study of diagnosis strategies of acute viral infections in Ukraine
Background: Efficient and accurate laboratory diagnosis of viral pathogens is of primary importance for clinical care in terms of health care system reforms. The methodological approach of cost-effectiveness analysis of...
Pharmaceutical Policies under Economic Crisis: The Greek case
Introduction: The purpose of this paper is to critically assess the Pharmaceutical reforms implemented in Greece before and during the economic crisis. The effects of the crisis are multiple in terms of GDP reduction, se...
Mepolizumab: a new drug programme for patients with severe eosinophilic asthma
Biological treatment involves more and more fields of medicine. This also applies to severe asthma for which a therapy with omalizumab (anti-IgE antibodies for patients with allergic asthma) has been available since 2013...
Diabetic Macular Edema treatment limits in Poland
iabetic Macular Edema (DME) is a severe disease, related to Diabetic Retinopathy (DR). All diabetic patients are at risk of DME development. The disease severity may vary from mild to moderate, with a risk of loss of vis...